Healthcare and pharma are among the hardest hit in cyberattacks. Globally, a single breach results in loss US$ 9.77 million. 27% of pharmaceutical companies globally reported data breaches costing between $1 million and $9.9 million, while 4% experienced breaches that exceeded $20 million in losses.
Pharma companies and clinical research organizations (CROs) are increasingly adopting hybrid cloud infrastructure to safeguard sensitive patient information. It combines the stringent control of private servers with the elasticity of public cloud services, allowing pharma manufacturers and hospitals to scale diagnostic systems, clinical trial platforms, and data-heavy research in real time, without compromising on compliance protocols or risking patient confidentiality.
Hybrid protects sensitive company data in the event of a cyberattack. A breach in one area does not cascade into others, ensuring operations can continue even under pressure. Pharma workflows involve software that aligns with regulatory expectations. What the hybrid cloud allows is a transition without disruption. New tools, powered by AI and analytics, can be deployed through public cloud channels.
【MORE】